Back to Alzheimers Disease

NCT05575076

NCT05575076
Terminated Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You must have already completed one of two specific earlier studies called RETHINK-ALZ or REFOCUS-ALZ.
  • You still show signs and symptoms that are consistent with Alzheimer's disease.
  • You have a study partner (such as a family member or caregiver) who is available to take part alongside you.

Who may not be able to join:

  • You currently live in a skilled nursing facility where you need round-the-clock care.
  • You have another brain or nervous system condition (separate from Alzheimer's) that is also significantly contributing to your memory or thinking problems.
  • You currently have a significant mental health diagnosis other than Alzheimer's disease.
  • You have another serious medical condition (unrelated to Alzheimer's) that is not stable or well-controlled.
  • You have any medical condition that the study doctor feels could affect your safety or your ability to complete the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Terminated
Phase
Phase 3
Sponsor
Cassava Sciences, Inc.
Registry
clinicaltrials_gov
Start date
7 November 2022
Est. completion
31 January 2025

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada Puerto Rico 🇰🇷 South Korea 🇺🇸 United States

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of Participants With Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov